文献速递消化道肿瘤与早癌消化内镜

既往质子泵抑制剂使用对胃癌生存的影响:北欧五国人群队列研究

The Effect of Prior Proton Pump Inhibitor Use on Gastric Cancer Survival: A Population-Based Cohort Study in the 5 Nordic Countries.
PubMed 文献 · Am J Gastroenterol · 2026-06-09

该研究纳入北欧五国21,433例胃非贲门腺癌患者,按诊断前2年PPI使用情况分为未使用、轻度和重度使用组。结果显示,重度和轻度PPI使用均与5年疾病特异性死亡风险降低相关(调整HR分别为0.90和0.87),重度使用还与转移性疾病和晚期肿瘤分期风险降低相关。

要点

  • 诊断前PPI使用与胃非贲门腺癌5年疾病特异性死亡风险降低相关。
  • 重度PPI使用与转移性疾病和晚期肿瘤分期风险降低相关。
  • PPI使用未增加晚期疾病或死亡风险。

核心结论

  • 诊断前PPI使用可能不增加胃非贲门腺癌晚期疾病或死亡风险。

研究设计与样本

  • 基于北欧五国全国性登记的前瞻性人群队列研究,纳入21,433例胃非贲门腺癌患者。

主要发现

  • 重度PPI使用与5年疾病特异性死亡风险降低相关(调整HR=0.90,95%CI 0.86-0.94)。
  • 轻度PPI使用与5年疾病特异性死亡风险降低相关(调整HR=0.87,95%CI 0.84-0.91)。
  • 重度和轻度PPI使用与5年全因死亡风险降低相关,结果相似。
  • 重度PPI使用与转移性疾病风险降低相关(调整OR=0.70,95%CI 0.64-0.76)。
  • 重度PPI使用与晚期肿瘤分期风险降低相关(调整OR=0.71,95%CI 0.56-0.89)。

临床怎么用

  • 对于胃非贲门腺癌患者,诊断前PPI使用史不应被视为预后不良的危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Proton pump inhibitors (PPIs) might mask gastric cancer symptoms, leading to delayed diagnosis and worse oncological outcomes. However, current evidence is sparse and underpowered. This study aimed to elucidate whether PPI use influences oncological outcomes of gastric cancer in a well-powered study. METHODS: This population-based cohort study included individuals with gastric non-cardia adenocarcinoma from the 5 Nordic nations. Multiple nationwide registries provided prospectively collected data. The individuals were grouped into non-users, light users, or heavy PPI users during the 2-year period before diagnosis. The outcomes of 5-year disease-specific mortality (primary) and 5-year all-cause mortality were analyzed using Cox regression, providing hazard ratios (HR) with 95% confidence intervals (CI). The outcomes of metastatic disease and advanced tumor stage at diagnosis were analyzed using logistic regression, providing odds ratios (OR) with 95% CI. The risk estimates were adjusted for age, sex, country, year, comorbidity, and Helicobacter pylori treatment. RESULTS: Among 21,433 individuals with gastric non-cardia adenocarcinoma, there were 9,736 users and 11,697 non-users. Heavy and light PPI use were both associated with reduced risk of 5-year disease-specific mortality (adjusted HR = 0.90, 95% CI 0.86-0.94 and HR = 0.87, 95% CI 0.84-0.91, respectively), with similar results for 5-year all-cause mortality. Heavy PPI use was associated with decreased risks of presenting with metastatic disease (adjusted OR = 0.70, 95% CI 0.64-0.76) or advanced tumor stage (adjusted OR = 0.71, 95% CI 0.56-0.89). DISCUSSION: PPI use before gastric non-cardia adenocarcinoma diagnosis may not be associated with an increased risk of advanced disease at presentation or of increased mortality.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Duru O, Santoni G, Holmberg D, et al. The Effect of Prior Proton Pump Inhibitor Use on Gastric Cancer Survival: A Population-Based Cohort Study in the 5 Nordic Countries. Am J Gastroenterol. 2026. PMID: 42262519. doi:10.14309/ajg.0000000000004075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。